市場調查報告書

全球輸卵管癌市場:成長,趨勢,預測

Global Fallopian Tube Cancer Market - Segmented by Therapy Type, and Geography - Growth, Trends, and Forecast (2018 - 2023)

出版商 Mordor Intelligence LLP 商品編碼 391492
出版日期 內容資訊 英文 112 Pages
商品交期: 2-3個工作天內
價格
全球輸卵管癌市場:成長,趨勢,預測 Global Fallopian Tube Cancer Market - Segmented by Therapy Type, and Geography - Growth, Trends, and Forecast (2018 - 2023)
出版日期: 2018年04月01日內容資訊: 英文 112 Pages
簡介

本報告提供全球輸卵管癌市場相關調查,彙整市場趨勢與今後的成長預測,治療類別,各地區趨勢,及打入市場的主要企業簡介等資料。

第1章 簡介

第2章 調查方法

第3章 摘要整理

第4章 主要推論

第5章 市場概要與產業趨勢

  • 目前市場方案
  • 市場概要
  • 波特五力分析

第6章 促進要素,阻礙要素,機會,課題分析

  • 推動市場的要素
  • 阻礙市場的要素
  • 市場機會
  • 課題

第7章 市場區隔

  • 治療類別
    • 手術
    • 化療
    • 放射線治療
  • 第8章 各地區佔有率及預測
  • 北美
  • 歐洲
  • 亞太地區
  • 中東·非洲
  • 南美

第9章 競爭環境

  • 合併·收購
  • 新產品上市
  • 協定,聯合,聯盟

第10章 企業簡介

第11章 投資的機會相關分析師預測

第12章 市場未來發展預測

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 48315

The global fallopian tube cancer market is expected to register a CAGR of 5.2%, during the forecast period, (2018-2023). North America dominates the market, due to high healthcare expenditure in the region.

Increasing Health Care Expenditure

There are several governments' initiatives in developed nations all over the world to provide insurance to cancer patients, which allow them to opt for expensive surgeries and therapies involved in the treatment. This is owing to the fact that the number of cancer cases is increasing rapidly. According to a survey in 2017, about 609,640 Americans are expected to die of cancer that's more than 1,670 people a day. Cancer is the second most common cause of death in the US, exceeded only by heart disease. The increasing government intervention by increasing healthcare expenditure, for insuring cancer patients will boost the market growth heavily in the forecast period. Also, the rising awareness about this type of cancer may act as a major driver for this market.

Adverse Side Effects of Treatment and Toxicity of Drugs

Because many targeted drugs are still quite new, it's hard to say how long you can expect side effects to last. We do know that some of the side effects from standard chemo drugs can last a lifetime, such as when the drug causes long-term damage to the heart, lungs, kidneys, or reproductive organs. These side effects along with the high costs of treatment may hinder many patients to seek proper treatment. This, in turn, will affect the overall growth of this market.

North America to Dominate the Market

North America dominates the global fallopian tube cancer market, owing to high incidence of cancer and its early diagnosis due to availability of advanced technology, and growing popularity of non-invasive radiation therapies for cancer in the region. Asia Pacific is expected to grow during the forecast period, owing to factors, such as high incidence of cancer diseases, less stringent regulatory scenario, and presence of huge population base.

Key Developments in the Market

March 2017: The U.S. Food and Drug Administration approved niraparib (ZEJULA) of Tesaro, Inc., a poly ADP-ribose polymerase (PARP) inhibitor, for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy

Major Players: AMGEN INC., ASTRAZENECA, BAYER, BOEHRINGER INGELHEIM GMBH, BRISTOL-MYERS SQUIBB, CELGENE, ELI LILLY AND COMPANY, AND F. HOFFMANN-LA ROCHE AG, amongst others.

Reasons to Purchase this Report

Current and future global fallopian tube cancer market outlook in the developed and emerging markets

Analysis of various perspectives of the market with the help of Porter's five forces analysis

The segment that is expected to dominate the market

Regions that are expected to witness fastest growth during the forecast period

Identify the latest developments, market shares, and strategies employed by the major market players

3 months analyst support, along with the Market Estimate sheet (in Excel)

Customization of the Report

This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.

Table of Contents

1. Introduction

  • 1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Key Inferences

5. Market Overview

  • 5.1 Current Market Scenario
  • 5.2 Porter's Five Forces Analysis
    • 5.2.1 Bargaining Power of Suppliers
    • 5.2.2 Bargaining Power of Consumers
    • 5.2.3 Threat of New Entrants
    • 5.2.4 Threat of Substitute Product and Services
    • 5.2.5 Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

  • 6.1 Market Drivers
    • 6.1.1 Rise in Awareness About Fallopian Tube Cancer and Available Therapies
    • 6.1.2 Increasing Health Care Expenditure
  • 6.2 Market Restraints
    • 6.2.1 High-Cost Associated with the Surgery and Therapy
    • 6.2.2 Adverse Side Effects of Treatment and Toxicity of Drugs
  • 6.3 Opportunities
  • 6.4 Key Challenges

7. Market Segmentation

  • 7.1 By Type of Therapy
    • 7.1.1 Surgery
      • 7.1.1.1 Salpingo-oophorectomy
      • 7.1.1.2 Cytoreductive/Debulking Surgery
      • 7.1.1.3 Others
    • 7.1.2 By Therapeutics
      • 7.1.2.1 Taxol (Paclitaxel)
      • 7.1.2.2 Cisplatin
      • 7.1.2.3 Pegylated liposomal doxorubicin (Caelyx)
      • 7.1.2.4 Topotecan (Hycamtin)
      • 7.1.2.5 Carboplatin
      • 7.1.2.6 Olaparib
      • 7.1.2.7 Bevacizumab
  • 7.2 By Geography
    • 7.2.1 North America
      • 7.2.1.1 United States
      • 7.2.1.2 Canada
      • 7.2.1.3 Mexico
    • 7.2.2 Europe
      • 7.2.2.1 France
      • 7.2.2.2 Germany
      • 7.2.2.3 United Kingdom
      • 7.2.2.4 Italy
      • 7.2.2.5 Spain
      • 7.2.2.6 Rest Of Europe
    • 7.2.3 Asia-Pacific
      • 7.2.3.1 China
      • 7.2.3.2 Japan
      • 7.2.3.3 India
      • 7.2.3.4 Australia & New Zealand
      • 7.2.3.5 South Korea
      • 7.2.3.6 Rest of Asia-Pacific
    • 7.2.4 Middle East & Africa
      • 7.2.4.1 GCC
      • 7.2.4.2 South Africa
      • 7.2.4.3 Rest of the Middle East & Africa
    • 7.2.5 South America
      • 7.2.5.1 Brazil
      • 7.2.5.2 Argentina
      • 7.2.5.3 Rest of South America

8. Competitive Landscape

  • 8.1 Mergers & Acquisition Analysis
  • 8.2 Agreements, Collaborations, and Partnerships
  • 8.3 New Products Launches

9. Key Players

  • 9.1 Amgen Inc.
  • 9.2 AstraZeneca
  • 9.3 Bayer
  • 9.4 Boehringer Ingelheim GmbH
  • 9.5 Bristol-Myers Squibb
  • 9.6 Celgene
  • 9.7 Eli Lilly and Company
  • 9.8 F. Hoffmann-La Roche AG
  • 9.9 List Not Exhaustive

10. Future of the Market